ENXTBR:ARGXBiotechs
New VYVGART Data Might Change The Case For Investing In argenx (ENXTBR:ARGX)
argenx SE recently presented new data for VYVGART® and its efgartigimod pipeline at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco.
These clinical updates, which include pivotal trial and real-world data across multiple patient subgroups, highlight advances in treating generalized myasthenia gravis and support ongoing innovation in rare neuromuscular...